-
Primidone: A Target-Aware Translational Framework
2026-09-10
Primidone (Mysoline) can serve as more than a repurposed antiepileptic: it is a target-aware probe spanning TRPM3, RIPK1, and translational biomarkers. This guide connects molecular assay design with ALS evidence while clarifying exposure, selectivity, and disease-model limitations.
-
DMH1: An ALK2 Inhibitor for Organoid Assays
2026-09-10
DMH1 is an ALK2 inhibitor that can serve as a pathway-resolved probe in pancreatic ductal organoids and NSCLC models. This article explains how to separate organoid formation, lineage composition, and cancer phenotypes when interpreting BMP pathway perturbation.
-
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-09-09
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to screen and improve the aqueous handling of poorly soluble hydrophobic compounds, particularly molecules with aromatic or phenyl groups. This dossier-based guide supports pharmaceutical and biochemical formulation workflows, but increased solubility should not be interpreted as proof of therapeutic efficacy, bioavailability, or suitability outside validated applications.
-
Methylprednisolone: Inflammation and Bone Models
2026-09-09
Methylprednisolone is a synthetic glucocorticoid receptor agonist used to interrogate cytokine control and glucocorticoid-associated skeletal injury. Its reported inhibition of TNF-alpha, modulation of NF-kappaB signaling, and defined rat-model parameters support reproducible research, but they do not establish clinical efficacy for bone preservation.
-
MALAT1–miR-125b–STAT3 Axis in Sepsis
2026-09-08
The reference study identifies a MALAT1–miR-125b–STAT3 regulatory axis that increases procalcitonin expression in sepsis-associated models. Its combination of clinical samples, LPS-stimulated U937 cells, RNA localization, interaction assays, and protein measurements provides a mechanistic framework for interpreting how a diagnostic biomarker may be regulated, while leaving clinical validation and in vivo causality unresolved.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-09-08
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic gene expression at the translation stage. Its compatibility with AAV delivery, light-sensitive cell systems, and tissue-accessible illumination suggests a practical route toward reversible gene therapies for metabolic and retinal disorders.
-
PPM-18: A Mechanistic Lens on Bone Inflammation
2026-09-07
PPM-18 is an NF-κB-linked iNOS expression inhibitor that can help researchers distinguish inflammatory transcription from downstream nitric oxide effects. This article develops a cautious, cross-domain framework for applying its mechanism to osteoimmune assay design without overstating evidence from sepsis or bone models.
-
CD38 CAR Binder Structure and Affinity Tuning
2026-09-05
Cheng and colleagues dissect how two CD38-targeting CAR binders engage distinct antigen surfaces and couple binding geometry to enzymatic inhibition. The study shows that rational affinity attenuation of 028 can reduce CAR-T fratricide while preserving antitumor cytotoxicity, offering a structure-guided framework for safer CD38-directed therapies.
-
Bacillus Media Shape γ-Glutamyl Peptide Production
2026-09-05
A December 2024 Food Bioscience study shows that both Bacillus strain selection and growth-medium composition shape γ-glutamyl peptide production, with hemoglobin hydrolysate generally supporting higher peptide concentrations than brain heart infusion broth. The findings also identify condition-specific glutathione formation and emphasize that medium composition may be a stronger process variable than strain identity.
-
Ivermectin for Reliable Cell Assay Workflows
2026-09-04
This scenario-driven guide shows how Ivermectin (SKU A2813) can support better-controlled viability, proliferation, and cytotoxicity workflows. It covers solvent compatibility, concentration calculations, assay optimization, interpretation limits, and evidence-based product selection for parasitology and exploratory oncology research.
-
PRINT: RNA-Mediated Transgene Insertion at Safe Harbors
2026-09-04
The reference study introduces PRINT, an RNA-only strategy that uses avian R2 retroelement proteins to insert transgenes at a multicopy human safe-harbor locus through target-primed reverse transcription. Its combination of site-directed integration, separate protein-encoding and template RNAs, and measurable activity in primary human cells addresses important limitations of CRISPR-mediated repair and viral delivery.
-
Ivermectin Workflows for Parasitology Research
2026-09-03
Build reproducible Ivermectin assays around solvent control, prompt solution use, orthogonal parasite readouts, and analytical verification. The workflow also shows how a recent pancreatic cancer study can improve assay design without overstating evidence for cross-domain applications.
-
BAPTA: Mapping Calcium-Driven Apoptosis
2026-09-03
A mechanistic guide to using BAPTA as a calcium chelator for testing the IP3R/Ca2+/STAT3 axis, strengthening apoptosis research, and translating environmental exposure findings into better experimental decisions.
-
TRAP-1 Reactivates p53Y220C Through Induced Proximity
2026-09-02
The bioRxiv preprint reports TRAP-1, a chemical inducer of proximity that assembles mutant p53Y220C with BRD4 to restore transcriptional activity. Its activity depends on ternary-complex formation, providing a mechanistic framework for reactivating selected tumor-suppressor mutants rather than merely stabilizing them.
-
HyperTrap Heparin HP Column for Stemness Research
2026-09-02
A translational strategy for using heparin affinity chromatography to connect CCR7–Notch1 stemness biology with reproducible protein enrichment, orthogonal validation, and research prioritization.